Medica Sur SA de CV

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: MXP510121215
MXN
56.00
-1 (-1.75%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Medica Sur SA de CV stock-summary
stock-summary
Medica Sur SA de CV
Pharmaceuticals & Biotechnology
Medica Sur SAB de CV is a Mexico-based company primarily engaged in the healthcare sector. The Company manages hospitals, emergency and diagnostic centers, medical laboratories, organ and blood banks, as well as an accommodation place. It provides medical services within various specializations, such as anatomic pathology, cardiology, gynecology and obstetrics, neonatology, neurophysiology, odontology, oncology, ophthalmology, orthopedics, otolaryngology, pediatrics, radiology and imaging, as well as radiosurgery. In addition, the Company offers medical tourism services and distributes drugs. It forms a part of Mayo Clinic Care Network. The Company operates through a range of subsidiaries, such as Corporacion de Atencion Medica SA de CV, El Portal Medico SA de CV, Servicios de Administracion Hospitalaria SA de CV and Telemed SA de CV. The Company is owned by Neuco SA de CV.
Company Coordinates stock-summary
Company Details
Puente de Piedra 150, Col. Toriello Guerra TLALPAN None : 14050
stock-summary
Tel: 52 55 5424720052 5 4247200
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Misael Uribe Esquivel
Chairman of the Board, Executive President
Mr. Juan Carlos Griera Hernando
Chief Executive Officer, Director
Dr. Octavio Gonzalez Chon
Medical Director, Director
Mr. Genaro Borrego Estrada
Director
Dr. Fernando Bernardo Gabilondo Navarro
Director
Dr. Martha Helena Ramos Ostos
Director
Eng. Santiago Chico Servitje
Director, Laboratory Director
Mr. Mario Federico Sicilia Benard
Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,181 Million
(Quarterly Results - Jun 2025)
Net Profit:
136 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

MXN 6,153 Million (Micro Cap)

stock-summary
P/E

11.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.02%

stock-summary
Debt Equity

-0.22

stock-summary
Return on Equity

20.95%

stock-summary
Price to Book

2.40